Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...
A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...
Richter transformation develops in 2%–10% of CLL cases, often with rapid clinical decline, limited chemotherapy efficacy, and restricted transplant eligibility due to age, comorbidity, and disease ...
CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), today announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) clinical program in non-small cell lung ...
ANKTIVA, in combination with an immune checkpoint inhibitor, has received accelerated approval from the Saudi Food and Drug Authority for the treatment of metastatic non-small cell lung cancer, ...
Feasibility Study for Using Large Language Models to Identify Goals-of-Care Documentation at Scale in Patients With Advanced Cancer A retrospective analysis of 3,626 patients treated with ICIs for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results